RxDoctor Payments Data

Mila Riehl, MD

Internal Medicine · Decatur, ALNPI 1003848706

Payments from drug & device makers

$1,392in general payments, 2019–2025

Across 82 payments — averaging $16.98 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$400
  • Novo Nordisk$182
  • AbbVie$160
  • Esperion Therapeutics, Inc.$99
  • Boehringer Ingelheim$93
  • Exact Sciences$70
  • plus $389 from 14 others

What the payments were for

  • Food & beverage$1,392100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,392 in reported general payments places this provider in the 65th percentile of 1,533 internal medicine providers in Alabama.

See all internal medicine providers in Alabama

Medicare billing

Part B allowed, 2024
$206,508
Medicare patients
261
Services billed
3,893

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin268$279,874
OzempicSemaglutide211$261,891
Trelegy ElliptaFluticasone/Umeclidin/Vilanter250$205,925
JanuviaSitagliptin Phosphate81$102,417
EliquisApixaban81$91,604
FarxigaDapagliflozin Propanediol66$83,266
Breztri AerosphereBudesonide/Glycopyr/Formoterol64$54,433
TrulicityDulaglutide27$53,703
XareltoRivaroxaban32$36,588
MyrbetriqMirabegron43$34,258
MounjaroTirzepatide32$33,522
LinzessLinaclotide28$29,912
Lantus SolostarInsulin Glargine,hum.Rec.Anlog77$15,004
NexlizetBempedoic Acid/Ezetimibe20$11,930
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog11$11,050

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance, Combivent Respimat, Tradjenta$93$300,183297 claims
Novo NordiskOzempic$182$261,891211 claims
AstraZenecaFarxiga, Breztri Aerosphere, Brilinta, Symbicort$400$147,619153 claims
MerckJanuvia$14$102,41781 claims
PfizerEliquis$13$91,60481 claims
Lilly USA, LLCTrulicity, Mounjaro$39$87,22559 claims
AbbVieLinzess$160$29,91228 claims
Esperion Therapeutics, Inc.Nexlizet$99$11,93020 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 1,533 internal medicine providers in Alabama.

Other internal medicine in Decatur

See the full list for Alabama

Where these figures come from

Is this you, or does something look wrong? →